This cancer-specific Reference Standard contains 22 variants across 19 genes relevant to the genetic testing of myeloid cancer. Horizon's cell line-derived Reference Standards are developed for the validation of NGS, PCR-based tests and other novel assays used for the sequencing of myeloid samples.
Features:
Cell line-derived control for the closest representation of your patient sample
ddPCR /Sanger validation for 22 variants with defined allelic frequencies
Contains a novel 300bp insertion in FLT3
Variants present at 5% - 70% allelic frequencies
Genes and Variants
19 genes relevant to myeloid cancer
22 variants
16 SNPs (SNVs), 6 INDELs
More information
Company Info:
Horizon Discovery Group plc (LSE: HZD) (“Horizon”), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health. Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines. Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.
Contact Information:
Horizon Discovery Ltd. 8100 Cambridge Research Park, Waterbeach, Cambridge CB25 9TL
Phone: +44 (0) 1223 976000
Email: info@horizondiscovery.com
